Indeed, our results confirm that obesity is related to an atherothrombotic risk that should be considered and, in line with our studies in humans, highlight the relevance of further studying GPVI as anti-thrombotic drug target in obesity. Here, GP6 is linked to obesity due to melanocortin 4 receptor deficiency.